ViaCyte Raises $10.6 Mln
ViaCyte said Wednesday it raised $10.6 million by selling Series C-1 Preferred Stock, together with warrants to purchase stock to existing investors Johnson & Johnson Development Corp., Sanderling Ventures and Asset Management Company (Johnson Trust). Atlanta-based ViaCyte is developing a cell therapy for the treatment of diabetes.
10 July 2013•4 mins read
